Cibc Asset Management Inc Mersana Therapeutics, Inc. Transaction History

Cibc Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$4.0 - $7.02 $360,404 - $632,509	-90,101 Reduced 15.9%	476,684 $1.96 Million
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $3.2 Million - $4.45 Million	566,785 New	566,785 $3.32 Million
Q2 2022 Aug 09, 2022	SELL	$2.84 - $5.0 $3 Million - $5.28 Million	-1,055,994 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$5.48 - $9.86 $15,365 - $27,647	-2,804 Reduced 0.26%	1,055,994 $6.57 Million
Q3 2021 Nov 09, 2021	BUY	$8.56 - $14.47 $2,499 - $4,225	292 Added 0.03%	1,058,798 $9.98 Million
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $9.71 Million - $13.2 Million	730,887 Added 223.09%	1,058,506 $14.4 Million
Q1 2021 May 14, 2021	BUY	$15.31 - $26.52 $5.02 Million - $8.69 Million	327,619 New	327,619 $5.3 Million

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $74.8M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.